STEVENSON, Md., March 29, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) common stock during the period between February 28, 2014 and January 31, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 3, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Psychemedics common stock during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Psychemedics’ Brazilian distributor, Psychemedics Brazil, was engaged in illegal anti-competitive practices and may be subject to further investigation by Brazil’s Administrative Council for Economic Defense as a result of the conduct.
According to the complaint, following a January 31, 2017 press release announcing that a Brazilian court had found Psychemedics Brazil in violation of anti-competition laws and liable for millions in losses, the value of Psychemedics shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Psychemedics common stock purchased on or after February 28, 2014 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal
BlueScope Steel Announces A$1 Special Dividend After Asset Sales
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
AFT Leaves X Over AI-Generated Images of Minors
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 



